137
Participants
Start Date
July 27, 2020
Primary Completion Date
September 19, 2024
Study Completion Date
September 19, 2024
Relacorilant
Relacorilant is supplied as blister-packed capsules for oral dosing. Relacorilant 400 mg dose consists of 4 relacorilant 100-mg capsules. Relacorilant 100-mg, 200-mg, and 300-mg doses are each given as a combination of 4 capsules containing relacorilant 100-mg and placebo as per the assigned dose.
Placebo
Placebo is supplied as blister-packed capsules for oral dosing. Each dose consists of 4 capsules containing placebo.
Site 25, Vienna
Site 44, New York
Site 52, Torino
Site 10, Jamaica
Site 40, Milan
Site 36, Baltimore
Site 01, Wilmington
Site 14, Málaga
Site 02, Summerville
Site 07, Atlanta
Site 51, Padua
Site 27, Birmingham
Site 06, Jackson
Site 13, Seville
Site 30, Cleveland
Site 26, Valencia
Site 16, Indianapolis
Site 33, Rochester
Site 09, Metairie
Site 20, Dallas
Site 05, Fort Worth
Site 08, Houston
Site 03, El Paso
Site 28, Napoli
Site 50, Munich
Site 54, Reno
Site 53, Torrance
Site 17, Stanford
Site 46, Würzburg
Site 15, Spokane
Site 32, Ramat Gan
Site 11, Fall River
Site 21, Columbus
Site 22, Sofia
Site 23, Tel Aviv
Site 43, Orbassano
Site 34, Milan
Site 35, Lublin
Site 31, Rome
Site 37, Rome
Site 48, Gliwice
Site 47, Krakow
Site 42, Bucharest
Site 38, Bucharest
Site 41, Bucharest
Lead Sponsor
Corcept Therapeutics
INDUSTRY